{
    "nct_id": "NCT04771390",
    "official_title": "An Open-label, Phase I Study to Evaluate the Relative Bioavailability, Food Effect and Pharmacokinetic Linearity of 2 New Tablet Formulations (Adult and Pediatric) of Selitrectinib (BAY 2731954) in Relative to Oral Suspension and the Liquid Service Formulation in Healthy Adult Participants",
    "inclusion_criteria": "* Participants who are overtly healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history, laboratory tests, physical, cardiac and neurologic examination\n* Body mass index (BMI): ≥18.5 and ≤ 29.9 kg/m2, with body weight ≥50 kg\n* Use of adequate contraception until 3 months after last study intervention\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* Existing relevant diseases of vital organs (e.g. liver diseases, heart diseases), central nervous system (e.g. seizures) or other organs (e.g. diabetes mellitus).\n* Medical history of risk factors for Torsades de pointes (e.g. family history of Long QT Syndrome) or other arrhythmias\n* Known severe allergies, allergies requiring therapy with corticosteroids, non-allergic drug reactions, or (multiple) drug allergies (excluding untreated asymptomatic seasonal allergies such as non-severe hay fever during the time of study conduct).\n* Regular use of medicines\n* Regular alcohol consumption\n* Smoking more than 5 cigarettes daily\n* History of COVID-19 or current SARS-CoV-2 infection",
    "miscellaneous_criteria": "Key"
}